At ASH 2018 editorial board member, Dr Mohamad Mohty, discusses Epstein-Barr virus associated post-transplant lymphoproliferative disorder (EBVPTLD) and developments in its treatment. EBVPTLD is a serious, life-threatening condition which can occur as a result allogeneic stem cell transplantation or organ transplantation, due to immunosuppression. One of the big topics at this year’s ASH was cellular therapy with cytotoxic T lymphocytes (CTLs), which could be an important tool for EBVPTLD. Dr Mohty explains that recent studies in patients treated with CTLs have shown good response rates and favourable safety profiles. Though CTL trials are still ongoing, Dr Mohty would like to see this therapy utilised in the near future.
1. What unmet needs and challenges do you face when treating patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder? (0:10)
2. Can you give us a brief overview of the mode of action of cytotoxic T lymphocyte (CTL) therapy? (2:03)
3. How will these findings be translated into clinical practice? When are EU and US filings expected, and what will this mean for patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder? (3:36)
4. What are the next steps in this area of research? What future opportunities are there in the development of CTLs and other cellular therapies? (4:37)
Speaker disclosures: Mohamad Mohty has nothing to disclose in relation to this interview.
Filmed at the 60th American Society of Hematology (ASH) 2018 Annual Meeting, San Diego, CA, US, 1–4 December 2018.
Share this Video
Related Videos In Haematology
Steven Pipe, ASH 2020 – First Results from the HOPE-B Gene Therapy Trial
We had the pleasure to talk to Steven Pipe (University of Michigan, Ann Arbor, MI, USA) to discuss the use of gene therapy for the treatment of haemophilia B. The abstract ‘First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe […]
Efstathios Kastritis, EHA 2020: CYBORD in Amyloidosis and The ANDROMEDA Study
touchONCOLOGY joins Dr Efstathios Kastritis (Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece) at EHA25 Virtual to discuss the ANDROMEDA study (NCT03201965), and the efficacy and safety of daratumumab in combination with CYBORD for the treatment of newly-diagnosed light chain amyloidosis. Questions: What are the major therapeutic […]
George Goshua, EHA 2020: Endotheliopathy is Essential in COVID-19 Associated Coagulopathy
Dr George Goshua (Yale University School of Medicine, New Haven, CT, USA) shares with us his insights into the role of endotheliopathy in the development of coagulopathy in patients with COVID-19. Questions: 1. How common is coagulopathy in COVID-19 infection and who is at greatest risk? (0:03) 2. What is known about the role of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!